Skip to content

Prevention Strategy of Postpartum Hemorrhage in Twin Cesarean Deliveries

Prevention of Postpartum Hemorrhage with Oxytocin and Ergometrine in Twin Cesarean Deliveries: A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127079
Enrollment
Unknown
Registered
2026-06-24
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage

Interventions

control group:Oxytocin + Placebo After delivery of the second fetus, oxytocin 10 IU was administered intravenously in 500 mL of normal saline, concurrently with a placebo injection given intramuscular
Intervention group:Oxytocin + Ergometrine After delivery of the second fetus, oxytocin 10 IU was administered intravenously in 500 mL of normal saline, and Ergometrine 0.2 mg was given intramuscularly

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women aged >= 18 years; 2. Twin pregnancy confirmed by ultrasound; 3. Gestational age >= 34+0 weeks; 4. Elective cesarean section (non emergency); 5. Preoperative hemoglobin >= 90g/l; 6. ASA class II-III; 7. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Known allergy to oxytocin or ergometrine; 2. Contraindications for ergometrine use (such as hypertension, cardiovascular disease, etc.); 3. Placenta previa; Placenta accreta; Suspected placenta accreta; 4. Known coagulation dysfunction or platelet count = 5cm; or multiple fibroids with more than 3 and a single fibroid >= 2cm; 7. Polyhydramnios (amniotic fluid index > 24cm); 8. Macrosomia (estimated weight of any fetus > 4000g); 9. Other operations (such as ovarian cyst removal, uterine fibroids removal, etc.) are required during the operation; 10. Participating in other clinical studies; 11. The researcher believes that it is not suitable to participate in this experiment.

Design outcomes

Primary

MeasureTime frame
Incidence of the composite outcome of postpartum hemorrhage and related complications within 24 hours postpartum.;

Secondary

MeasureTime frame
Severe postpartum hemorrhage (>=1000 mL) within 24 hours postpartum.;Proportion of patients requiring additional second?line uterotonics.;The magnitude of hemoglobin decrease at 24 and 48 hours postoperatively.;Cardiovascular adverse events;Quality of postoperative recovery;

Countries

China

Contacts

Public ContactHongbo Qi

The First Affiliated Hospital of Chongqing Medical University

qihongbo728@163.com+86 23 63809721

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026